Stock Analysis, Dividends, Split History

SMLP / Summit Midstream Partners LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price16.05
Volume214,400.00
Market Cap ($M)1,162.07
Enterprise Value ($M)2,221.64
Book Value ($M)1,389.67
Book Value / Share19.01
Price / Book0.84
NCAV ($M)-1,427.07
NCAV / Share-19.53
Price / NCAV-0.81
Share Statistics
Common Shares Outstanding 73,085,996
Common Shares Outstanding2 1,490,999
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.03
Return on Equity (ROE)0.07
Balance Sheet (mrq) ($M)
Assets2,894.79
Liabilities1,505.12
Quick Ration/a
Current Ratio1.13
Income Statement (mra) ($M)
Oil And Condensate Revenue68,459,000.00
Gas Gathering Transportation Marketing And Processing Revenue394,427,000.00
Other Sales Revenue Net25,855,000.00
Revenues488,741,000.00
Net Income86.05
Cash Flow Statement (mra) ($M)
Cash From Operations237.83
Cash from Investing-148.68
Cash from Financing237.83
Identifiers and Descriptors
CUSIP866142102
Central Index Key (CIK)1549922
Related CUSIPS
866142952 866142902

Split History

Stock splits are used by Summit Midstream Partners LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

10 Energy Sector Top Target Gains Range 24.6%-83.8% From September Dividend WallStars

2018-09-07 seekingalpha
Energy equities with over .72% Broker Target Upsides showed midstream firms tops on the list, Sanchez, for price upside and American Midstream for net gains, and yield as of 9/6/18. (4-1)

A 13% Yield For Patient Income Investors

2018-08-24 seekingalpha
Management has big growth projects coming on board in the second half of 2018 and first half of 2019. (10-0)

Summit Midstream: An Undervalued Play On North America's Primary Energy Basins

2018-08-17 seekingalpha
Summit Midstream is one of the few MLPs that has operations in seven different resource plays throughout the United States.

Midstream Rally Secured

2018-08-12 seekingalpha
Midstream traded up for a 6th straight week, with MLPs again out front with a 2.2% total return. The MLP Index's YTD total return is now nearly 12% after being negative less than a month ago. The broad market struggled a bit, and midstream was a safe place to hide on Friday when the broad market sold off on Turkey's currency plunge. (6-0)

Stocks To Watch: Any Privacy For Tesla?

2018-08-11 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (217-5)

CUSIP: 866142102